Letermovir denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for letermovir are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Letermovir as Not FDA-Approved — and Why This Is Appealable

A "not FDA-approved" denial for letermovir is one of the most fact-checkable denials in the pharmacy benefits system. Letermovir has received FDA approval for CMV prophylaxis in specific transplant populations; if Humana is issuing this denial, it almost always reflects one of three situations: (1) a claim-processing error or outdated plan policy that predates the FDA approval; (2) the patient's specific indication or transplant type falls outside the FDA-approved labeling; or (3) a coding or diagnosis mismatch between the claim and the approved indication. Identifying which situation applies determines the appeal strategy.

## The Federal Legal Framework

• ERISA §503: Humana must provide a full-and-fair review with the specific basis for the not-FDA-approved determination.
• ACA §2719: independent external review is available, generally within approximately four months of denial, with expedited review for urgent transplant situations. External reviewers routinely reverse not-FDA-approved denials when the drug carries a current FDA approval that covers the patient's indication.

## Concrete Appeal Steps and Timeline

1. Confirm the FDA approval status: the prescriber should retrieve the current FDA-approved prescribing information for letermovir and confirm the patient's indication matches the approved label. 2. Request the denial rationale: Humana must specify which aspect of approval status it is relying on — this tells you whether it is a policy lag, an off-label use, or a coding issue. 3. Internal appeal: file within the deadline in the denial letter (commonly 180 days). Attach the FDA approval documentation directly. 4. Expedited internal review: request this given the post-transplant urgency; Humana must respond within 72 hours. 5. External review: file for IRO review if denied internally; present the FDA approval label as the primary evidence.

## Documentation to Gather

• FDA prescribing information: the current FDA label for letermovir, specifically the approved indication section — confirm it covers the patient's transplant type and clinical situation.
• Transplant record: documentation of transplant type, date, and clinical context linking the patient's situation to the approved indication.
• CMV serostatus labs: donor and recipient CMV IgG serostatus to establish the clinical indication.
• Claim/diagnosis alignment: review the ICD-10 diagnosis codes on the claim and confirm they match the FDA-approved indication; correct any mismatch before resubmitting.
• Prescriber letter: a letter from the transplant physician explicitly linking the patient's diagnosis and transplant type to the FDA-approved indication for letermovir.
• If off-label: if the use is genuinely off-label, shift the argument to medical necessity with guideline support from the relevant transplant society, and note that off-label use of FDA-approved drugs is recognized under ACA and ERISA appeal rules when supported by authoritative clinical evidence.

## Criteria-Mapping Structure

Build a two-column table: left column states Humana's basis for the not-FDA-approved denial; right column provides the FDA label reference, chart fact, or coding correction that directly refutes it. If the denial is a policy-lag error, that argument alone often resolves it at the first internal review. If it is an off-label situation, the external reviewer will assess whether the use is supported by the applicable standard of care — a robust prescriber letter and guideline citation give that argument a strong foundation.